Tokyo, Jan. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060353) titled 'A multicentre observational registry study of chemoradiotherapy followed by durvalumab in limited stage small cell lung cancer' on Jan. 20.
Study Type:
Observational
Primary Sponsor:
Institute - other
Condition:
Condition - limited stage small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate real-world PFS (rwPFS) from the start of durvalumab in LS-SCLC patients who are treated with cCRT followed by durvalumab
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender ...